key: cord-0289506-ayqzww28
authors: Takayama, Wataru; Endo, Akira; Otomo, Yasuhiro
title: Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study
date: 2022-05-27
journal: nan
DOI: 10.1016/j.ajem.2022.05.031
sha: bd95ecafeca9735c1a951e56fdc4f519c0fde798
doc_id: 289506
cord_uid: ayqzww28

Background Although several reports recommend the use of systemic anticoagulation therapy in patients with severe coronavirus disease 2019 (COVID-19) pneumonia, appropriate target population and timing of administration are unknown. We assessed association between therapeutic anticoagulation administration with unfractionated heparin and outcomes in patients with severe COVID-19 pneumonia, assuming that anticoagulant administration effects are influenced by therapy timing. Methods This retrospective observational study included severe COVID-19 patients requiring mechanical ventilation in a tertiary emergency critical care hospital intensive care unit (ICU) in Japan from May 1, 2020 to September 30, 2021. All included patients were divided into early and late-phase administration groups based on therapeutic anticoagulant administration timing (≤5 and > 5 days, respectively, after commencing oxygen therapy). Primary outcomes (in-hospital mortality and adverse events related to anticoagulation therapy) and secondary outcomes [veno-venous extracorporeal membrane oxygenation (ECMO), ventilator-free days (VFD), and ICU-free days] were compared between groups using univariate and multivariate models. Results Of 198 included patients 104 (52.5%) and 94 (47.5%) were in early-phase and late-phase administration groups, respectively. Although background characteristics were similar between the groups, the early-phase administration group had a significantly lower in-hospital mortality rate (3.8% vs. 27.7%; p < 0.001), lower adverse event rates (1.9% vs. 12.8%; p < 0.001), significantly longer VFD and ICU-free days, and lower ECMO rates, than the late-phase administration group, in the multivariate model. Conclusions Late administration of therapeutic-dose anticoagulation in patients with severe COVID-19 pneumonia was significantly associated with worse outcomes than early administration.

The coronavirus disease 2019 (COVID- 19) pandemic, an ongoing public health problem, has caused the death of more than 4.8 million people worldwide, as of the end of September 2021 [1] . COVID-19 induces a cytokine storm that activates a coagulation cascade, resulting in coagulopathy and thrombotic phenomena, which leads to multiple organ dysfunction and high mortality [2] . The inflammation and thrombosis associated with endothelial dysfunction and hypercoagulability lead to an increased risk of micro (or macro) vascular thrombosis [3, 4] .

Thus, guidelines from several medical organizations recommend the use of anticoagulation therapy in patients with COVID-19 [5] .

A large cohort study [6, 7] reported that the use of anticoagulation at therapeutic doses may be associated with a reduced risk of mortality among hospitalized patients with COVID-19.

Although a recent randomized control trial (RCT) has reported that therapeutic-dose anticoagulation did not decrease the mortality rate and the number of organ support free days, the severity of included patients was relatively low, and the date of onset of symptoms was not considered [8] . Meanwhile, another recent RCT demonstrated a clear benefit of therapeutic dose anticoagulation for non-critically ill patients with COVID-19 [9] . Therefore, the appropriate target population and timing of the administration of therapeutic anticoagulants are still under debate.

Based on this background, in the present study, we assessed the association between the administration of therapeutic-dose anticoagulant therapy and the outcomes in patients with severe COVID-19 pneumonia, assuming that the effects of therapeutic anticoagulant administration are affected by the timing of the therapy.

This was a single-center retrospective observational study conducted at the intensive care unit J o u r n a l P r e -p r o o f Journal Pre-proof

Patients with COVID-19 were transferred to the ICU and underwent mechanical ventilation if they could not maintain an arterial oxygen partial pressure to fractional inspired oxygen (PaO 2 /FiO 2 ) ratio of less than 200 after oxygen therapy in our hospital. All included patients received unfractionated heparin (UFH) within the first 6 h after ICU admission, and their activated partial thromboplastin time was monitored and maintained at 1.5 to 2.5 times that of the control. During the study period, when anticoagulation therapy-related adverse events occurred, or the patients were discharged from the ICU, these therapies were discontinued immediately.

Data were collected by trained medical doctors, and a standard abstraction form was used to ensure uniform data handling. Collected data were monitored, and suspected outliers were confirmed or corrected by other chart abstractors. The following information was retrospectively collected from the patients' medical records: age, sex, body mass index, date of disease onset, date of oxygen therapy, history of anticoagulant and/or antiplatelet therapy, smoking history, Charlson Comorbidity Index score [10] , administration of ECMO, drug treatment for COVID-19, and status on hospital discharge (i.e., dead or alive). The clinical course, length of ventilation, and ICU stay for each patient were also recorded. Furthermore, we collected laboratory results such as D-dimer, fibrin-fibrinogen degradation products (FDP), white blood cell count, and C- 

In this study, severe COVID-19 pneumonia was defined as an acute need for invasive mechanical ventilation. The "early-phase administration group" was defined as patients who received therapeutic anticoagulation within 5 days after the commencement of oxygen therapy, while the "late-phase administration group" was defined as those who received it 6 days or after, pathogen from blood, lower respiratory tract (qualified sputum or endotracheal aspirate), or urine specimens after ICU admission [12] .

We defined the primary efficacy outcome as in-hospital mortality. The primary safety outcomes included anticoagulation therapy-related adverse events, defined as any of the following events: (1) hemoglobin level <7 g/dL and any red blood cell transfusion, (2) at least ventilator-free days (VFD) 28 days after admission, and ICU-free days within the first 28 days after admission.

In the univariate analysis, continuous variables were compared using Student's t-test or the Mann-Whitney U test. Categorical variables were compared using the χ 2 test or Fisher's exact test, as appropriate. First, using a multivariable logistic regression model, we evaluated the interaction between therapeutic-dose anticoagulant therapy and the days from commencement of oxygen therapy to the anticoagulant therapy for the primary outcome, to determine whether the timing of therapeutic anticoagulation influenced the outcomes. We incorporated age and SOFA score, which are known a priori to be associated with outcomes in patients with severe COVID-19 pneumonia [13] [14] [15] , and selected variables based on clinical plausibility and the number of outcomes (10 events per variable rule) as covariates in the multivariate model. Second, we divided the enrolled patients into two groups: the early-phase administration group (≤5 days after the commencement of oxygen therapy) and the late-phase administration group (>5 days after the commencement of oxygen therapy) based on the median number of days from oxygen therapy administration to therapeutic anticoagulation administration. We then compared the characteristics, severity, and outcomes of both groups. Furthermore, we divided the enrolled patients into two groups based on the another cut-off value (7 days) and performed a sensitivity analysis of the primary and secondary outcomes. All statistical analyses were conducted using R J o u r n a l P r e -p r o o f

The patient selection process is shown in Figure 1 . Among 606 potentially eligible patients with COVID-19, 198 (32.7%) patients with severe pneumonia underwent mechanical ventilation during the study period. Of these, 104 (52.5%) patients were treated with therapeutic anticoagulation in the early phase. Table 1 shows the main clinical characteristics, laboratory data at the initiation of mechanical ventilation, the worst clinical scores during the first 24 h after intubation, and the administered drugs during the ICU stay. The patients' laboratory data and severity scores were similar between the two groups. However, D-dimer and CRP levels, FDP, and severity scores tended to be higher in the late-phase administration group. Although the patients in both groups received similar treatments, the frequency of clinical complications was significantly higher in the late-phase administration group than in the early phase administration group. Table 3 presents the multivariate logistic regression analysis results adjusted for age and SOFA score. The late-phase administration of therapeutic-dose anticoagulants, compared to early phase administration, was significantly associated with higher in-hospital mortality, rates of adverse events, rates of ECMO administration, and shorter VFD and ICU-free days. Supplementary Tables 1, 2 and 3 show the result of the sensitivity analysis wherein the patients were grouped according to different criteria. The results were similar to the main findings.

In this retrospective observational study, we found that the timing of therapeutic anticoagulation therapy significantly influenced the outcomes in 198 patients with COVID-19 pneumonia requiring mechanical ventilation. Furthermore, our findings indicated that late administration compared to early administration of therapeutic-dose anticoagulation was significantly associated with higher in-hospital mortality, adverse events, and ECMO administration, as well as shorter VFD and ICU-free days. To the best of our knowledge, this is the first study to report the association between the timing of therapeutic dose anticoagulation and outcomes in patients with severe COVID-19 pneumonia.

In COVID-19 pneumonia, despite anticoagulant prophylaxis or therapy, several studies have reported life-threatening arterial or venous thrombosis, including frequent severe pulmonary embolisms [16, 17] . Such disease characteristics have led to the empirical treatment of patients with severe COVID-19 with heparin at therapeutic doses than at the usual thromboprophylaxis doses [18] . In addition to its known anticoagulant properties, heparin has been reported to have potential therapeutic effects in severe lung inflammation, impaired J o u r n a l P r e -p r o o f Journal Pre-proof pulmonary gas exchange, and high viral load [19] [20] [21] . Because SARS-CoV-2 infection causes an excessive inflammatory response that may lead to coagulation hyperactivity, anticoagulation therapy using heparin is expected to have positive effects on the outcomes based on potential antiviral mechanisms [21] in addition to anticoagulative effects. However, the optimal anticoagulant regimen remains unknown. A recent RCT did not support the hypothesis that routine therapeutic dose anticoagulation benefits patients with severe COVID-19 pneumonia [8] , possibly because the net effect of anticoagulation on clinical outcomes may depend on the timing of initiation in relation to disease course or severity. Further RCTs considering the timing of commencement are warranted to assess the effects of therapeutic anticoagulation.

In severe COVID-19 pneumonia cases, dramatic changes in the coagulation/fibrinolytic status on illness days 7-10 have been reported, where the status is changed from a hypofibrinolytic state to a hyper-fibrinolytic state [22, 23] . In this respect, late administration of therapeutic-dose anticoagulation in patients with severe COVID-19 could influence the fibrinolytic state, increasing bleeding risk. However, since the underlying mechanisms of the late-phase administration of therapeutic anticoagulation could not be elucidated by our clinical data, further research is warranted to reveal the differences in the effect between the early and late phases in patients with severe COVID-19.

Lymphopenia has been reported in most patients with severe COVID-19 pneumonia [24] , and immunosuppression is more obvious in severe cases than in mild cases [25] . In severe cases, immunosuppression has been reported to develop after more than 7 days of illness onset [26] . In this study, we found that the prevalence of secondary infection in the late-phase administration group was higher than that in the early-phase administration group ( Despite these limitations, we showed a novel and significant association between the J o u r n a l P r e -p r o o f Journal Pre-proof 

COVID-19: consider cytokine storm syndromes and immunosuppression

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

Coagulopathy of coronavirus disease 2019

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

The use of therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19: a systematic review

Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis

Therapeutic anticoagulation with heparin in critically ill patients with Covid-19

Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

The third international consensus definitions for sepsis and septic shock (Sepsis-3)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Surviving sepsis campaign: International guidelines for management of sepsis and septic shock

The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with metaanalysis

Factors associated with death in critically ill patients with coronavirus disease 2019 in the US

COVID-19 and its Implications for thrombosis and anticoagulation

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?

More than an anticoagulant: do heparins have direct anti-inflammatory effects?

The anti-inflammatory effects of heparin and related compounds

Coronaviridae and SARS-associated coronavirus strain HSR1

Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A nationwide cohort study

Immune dysfunction following COVID-19, especially in severe patients

Clinical course and risk factors for mortality of adult in patients withCOVID-19 in Wuhan,China: a retrospective cohort study

Unexpectedly high frequency of Enterococcal Bloodstrean infections in coronavirus disease 2019 patients admitted to an Italian ICU: an observational study

Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients

Fibrin-fibrinogen degradation products, median

Clinical scores SOFA score, median

Nafamostat mesylate, n (%)

intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment

Acute Physiology and Chronic Health Evaluation